FDA review of historic data shows patients who received robotic prostatectomies have overall cancer survival rates on par with open surgerySUNNYVALE, Calif., June 05, 2024 (GLOBE NEWSWIRE) -- Intuitive (NASDAQ:ISRG), a global technology leader in minimally invasive care and the pioneer of robotic-assisted surgery, announced today that the U.S. Food and Drug Administration (FDA) cleared a labeling revision for da Vinci X and Xi specific to radical prostatectomy. This clearance was based on real-w
The latest trading day saw Intuitive Surgical, Inc. (ISRG) settling at $403.39, representing a +1.25% change from its previous close.
As Intuitive Surgical gets FDA clearance for its next-gen robotic surgery system, ISRG stock teases a new breakout.